Myriad Genetics (NASDAQ:MYGN) Updates FY25 Earnings Guidance

Myriad Genetics (NASDAQ:MYGNGet Free Report) updated its FY25 earnings guidance on Wednesday. The company provided EPS guidance of $0.07-0.11 for the period, compared to the consensus EPS estimate of $0.15. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $879.47 million. Myriad Genetics also updated its FY 2025 guidance to 0.070-0.110 EPS.

Myriad Genetics Stock Performance

NASDAQ:MYGN opened at $13.68 on Wednesday. The firm has a market cap of $1.25 billion, a PE ratio of -10.52 and a beta of 1.89. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The business has a 50 day moving average price of $15.05 and a 200-day moving average price of $22.17. Myriad Genetics has a fifty-two week low of $12.87 and a fifty-two week high of $29.30.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Leerink Partnrs lowered Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. Morgan Stanley dropped their target price on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a report on Monday, November 18th. Bank of America reduced their price objective on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a research report on Friday, December 13th. StockNews.com raised Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Thursday, January 9th. Finally, Leerink Partners downgraded Myriad Genetics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $30.00 to $21.00 in a research note on Monday, December 9th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $24.27.

Check Out Our Latest Report on MYGN

Myriad Genetics Company Profile

(Get Free Report)

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

Featured Articles

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.